PBH Stock Recent News

Prestige Consumer Healthcare Inc. (NYSE:PBH ) Q1 2026 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Christine Sacco - CFO & COO Philip David Terpolilli - Director of Investor Relations Ronald M. Lombardi - Chairman, President & CEO Conference Call Participants Anthony Chester Lebiedzinski - Sidoti & Company, LLC Douglas Matthai Lane - Water Tower Research LLC Glenn West - William Blair & Company L.L.C.

Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $0.95 per share, missing the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $0.9 per share a year ago.

Revenue of $249.5 million in Q1; decline driven by limited eye care supply Diluted EPS of $0.95 in Q1, up approximately 6% versus prior year Adjusted Diluted EPS of $0.90 Announces agreement to acquire current eye care supplier Pillar5 Pharma Revising fiscal 2026 revenue outlook to $1,100 to $1,115 million and Diluted EPS outlook to $4.50 to $4.58 TARRYTOWN, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter fiscal 2026 ended June 30, 2025.

Beyond analysts' top-and-bottom-line estimates for Prestige Consumer Healthcare (PBH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.

TARRYTOWN, N.Y., July 15, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2026 first quarter earnings release on Thursday, August 7, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

TARRYTOWN, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- Medtech Products Inc., a Prestige Consumer Healthcare Inc. company (“Medtech” or “Company”), is voluntarily recalling five lots of Little Remedies® Honey Cough Syrup (the “Product”) due to the presence of Bacillus cereus and loss of shelf-stability. Bacillus cereus (B. cereus) can cause two types of food-borne illnesses. One type is characterized by nausea, vomiting, and stomach cramps that can start 1 to 6 hours after eating or drinking contaminated food. The second type can cause stomach cramps and diarrhea that can start 8 to 16 hours after eating or drinking contaminated food. Diarrhea may be a small volume or profuse and watery. Although healthy individuals may suffer only short-term illness, exposure to high levels of foodborne B. cereus can cause death.

PBH rides strong on e-commerce gains and brand innovations, but debt load and forex risks cast a shadow on future growth.

TARRYTOWN, N.Y., June 09, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will participate in a fireside chat at the Oppenheimer 25th Annual Consumer Growth and E-Commerce Conference virtually on Wednesday, June 11, 2025 at 10:30 a.m. ET. A live webcast of this event will be available at www.prestigeconsumerhealthcare.com under the "Investors” section and the "Events and Presentations" tab, or by using the following link:

Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks is more attractive to value investors?